Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer patients; an in vivo study with positron emission tomography

Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer patients; an in vivo study with positron emission tomography - Imaging of [11C]erlotinib kinetics in non small cell lung carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32923

Enrollment

Registered

2009-09-14

Start date

2009-11-17

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients age of 18-70 years Patients with non small cell lung cancer planned to receive erlotinib Life expectancy of at least 12 weeks Malignant lesion of at least 1.5 cm diameter within the chest as measured by CT Performance status Karnofsky index >60% Laboratory requirements Written informed consent

Exclusion criteria

Exclusion criteria: Claustrophobia Pregnant or lactating patients Patients having metal implants (e.g. pacemakers) Concurrent or previous treatment with experimental drugs Haemoglobin level

Design outcomes

Primary

Measure	Time frame
Primary study parameters/outcome of the study: Change in [11C]erlotinib kinetics in EGFR mutated non small cell lung carcinoma (NSCLC) compared to non mutated EGFR NSCLC.	—

Secondary

Measure	Time frame
Secundary study parameters/outcome of the study: 1. Validation of the PET-CT study 2. Compare the venous and arterial plasma kinetics of [11C]erlotinib 3. Study the relationship between tumor blood flow and [11C]erlotinib kinetics in tumor tissue	—

Countries

Netherlands

Outcome results